In today’s nutraceutical and pharmaceutical market, the label “lactose-free” is not merely a commercial claim, but a true guarantee of safety and quality.
Lactose intolerance is a widespread condition worldwide and, for a significant portion of the population, even minimal amounts can cause gastrointestinal discomfort.
In this context, ensuring the actual absence of lactose in a food supplement or pharmaceutical product represents a concrete responsibility for manufacturing companies.
This issue becomes particularly relevant considering that lactose is one of the most widely used excipients in the pharmaceutical and nutraceutical industries: it is stable, functional, easily compressible, and cost-effective. Precisely because of its extensive use, the risk of cross-contamination or unintentional residues cannot be underestimated, especially when the product is intended for sensitive individuals.
Regulatory requirements for lactose content in food products often allow quantification limits around 10 ppm. However, in the pharmaceutical field, infant nutrition, or supplements intended for highly sensitive individuals, this threshold may not be considered sufficiently precautionary.
For this reason, a growing number of companies adopt stricter internal limits, sometimes below 1 ppm, in order to provide a higher level of protection and strengthen brand credibility.
Achieving these thresholds is not compatible with conventional analytical methods. It is necessary to rely on technologies with extremely high sensitivity and specificity.
To meet these needs, Biofarma Group has validated a highly sensitive analytical method for detecting lactose in food supplements, with the aim of ensuring maximum reliability for its clients.
The approach is based on UHPLC–MS/MS technology (Ultra High Performance Liquid Chromatography coupled with tandem mass spectrometry), considered the gold standard in this field.
The choice of this technology is driven by the need to ensure maximum accuracy, high sensitivity, high specificity, and reliability.
In both the pharmaceutical and food sectors, it is essential to have a technique capable of detecting and quantifying extremely low concentrations with high reproducibility.
Compared to traditional enzymatic or colorimetric methods, UHPLC–MS/MS provides superior analytical precision and allows differentiation between the different anomeric forms of lactose (α and β). The ability to distinguish and separately quantify the two forms further increases the method’s specificity and reduces the risk of false positives or matrix interferences—an essential aspect when analyzing complex formulations.
The method has been tested on a wide range of supplements and pharmaceutical products declared “lactose-free,” in compliance with international ISO 17025 and ICH Q2(R2) standards. The results confirmed that the validated analytical method is precise, specific, sensitive, and robust.
Specifically, it is capable of detecting and quantifying lactose even at trace levels thanks to its low limits of detection and quantification.
Furthermore, the method’s specificity was confirmed by the absence of interference in blank and placebo samples, ensuring reliable results even in complex matrices.
Finally, the method demonstrated linearity over a wide concentration range and good reproducibility across different operators and laboratories.
This means that Biofarma Group is able to offer its clients ultra-high-sensitivity quality control and tangible protection for products intended for sensitive populations, as well as technical and documentary support in the event of audits or inspections.
In an increasingly transparency- and responsibility-driven market, the ability to demonstrate the absence of lactose in nutraceutical products is not merely a technical requirement, but a real and measurable competitive advantage.
